Delayed
Nasdaq
03:59:10 2025-06-18 pm EDT
5-day change
1st Jan Change
519.94 USD
-0.12%
-0.81%
+25.76%
IDEXX Laboratories Q1 Earnings, Revenue Increase; 2025 Outlook Raised
Published on 05/01/2025 at 07:45
IDEXX Laboratories, Inc., Q1 2025 Earnings Call, May 01, 2025
01:07pm
Leerink Partners Adjusts IDEXX Laboratories Price Target to $580 From $515
Jun. 11
MT
IDEXX Laboratories, Inc. Announces the Launch of the Catalyst®? Cortisol Test
Jun. 05
CI
Idexx Laboratories - Launches Catalyst Cortisol Test For Diagnosing Addison's Disease And Managing Cushing's Syndrome In Dogs
Jun. 05
RE
IDEXX Laboratories, Inc. Presents at Stifel Jaws & Paws Conference 2025, May-28-2025 10:55 AM
May. 28
Stifel Adjusts Price Target on IDEXX Laboratories to $510 From $460, Maintains Hold Rating
May. 19
MT
BNP Paribas Exane Adjusts Price Target on IDEXX Laboratories to $577 From $566, Maintains Outperform Rating
May. 12
MT
BTIG Raises Price Target on IDEXX Laboratories to $545 From $530, Maintains Buy Rating
May. 05
MT
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $558 From $548, Maintains Overweight Rating
May. 05
MT
Leerink Partners Adjusts IDEXX Laboratories Price Target to $515 From $500
May. 02
MT
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999.
May. 01
CI
IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics
May. 01
RE
IDEXX Laboratories Q1 Earnings, Revenue Increase; 2025 Outlook Raised
May. 01
MT
Earnings Flash (IDXX) IDEXX Laboratories Posts Q1 Revenue $998.4M, vs. FactSet Est of $997.1M
May. 01
MT
Earnings Flash (IDXX) IDEXX Laboratories Posts Q1 EPS $2.96, vs. FactSet Est of $2.85
May. 01
MT
(IDXX) Idexx Laboratories Sees Fiscal Year 2025 EPS Range $11.93 - $12.43
May. 01
MT
Earnings Flash (IDXX) Idexx Laboratories Posts Q1 Revenue $998.4M, vs. FactSet Est of $997.1M
May. 01
MT
IDEXX Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
May. 01
CI
Idexx Laboratories, Inc. Updates Financial Guidance for 2025
May. 01
CI
BofA Trims Price Target on IDEXX Laboratories to $475 From $535, Maintains Neutral Rating
Apr. 21
MT
Leerink Partners Adjusts Price Target on IDEXX Laboratories to $500 From $525, Maintains Outperform Rating
Apr. 21
MT
Morgan Stanley Adjusts IDEXX Laboratories' Price Target to $548 From $559, Keeps Overweight Rating
Apr. 15
MT
Stifel Adjusts IDEXX Laboratories' PT to $420 From $450, Keeps Hold Rating
Apr. 14
MT
ImmuCell Corporation Appoints Timothy C. Fiori as Chief Financial Officer
Apr. 07
CI
IDEXX Laboratories, Inc. Presents at Raymond James & Associates? 46th Annual Institutional Investors Conference 2025, Mar-03-2025 11:35 AM
Mar. 03
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
IDXX: Dynamic Chart
IDEXX Laboratories, Inc. is a world leader in the design, development and marketing of diagnostic test instruments for animal health monitoring and analysis of dairy products and water. Net sales break down by area of application as follows:
- veterinary diagnoses for pets (91.8%);
- water quality analysis (4.7%);
- veterinary diagnoses for livestock and poultry (3.1%): solutions that help detect infectious diseases in ruminants, pigs, poultry and horses. The group also offers test solutions for dairy products;
- other (0.4%).
Net sales by source of income break down between product sales (57.7%) and services (42.3%).
Net sales are distributed geographically as follows: the United States (65%), Canada (3.9%), Americas (2.1%), Germany (4.5%), the
United Kingdom (3.5%), France (2.9%), Spain (1.6%), Italy (1.5%), Switzerland (0.9%), Netherlands (0.9%), Europe/Middle East/Africa (5.1%), Australia (2.5%), Japan (1.9%), China (0.9%) and Asia/Pacific (2.8%).
More about the company
Last Close Price
519.85 USD
Average target price
507.08 USD
Spread / Average Target
-2.46%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
Select your edition
All financial news and data tailored to specific country editions